Viral hepatitis is an inflammatory liver disease caused by infection with any of the known hepatitis viruses—A, B, C, D, and E. Most of the global viral hepatitis burden is from hepatitis B and C, which affect 354 million people and result in 1.1 million deaths annually. The Centers for Disease Control and Prevention estimates that in 2020 there were 14,000 and 50,300 new acute infections of...
As the International AIDS Society’s 12th Conference on HIV Science (IAS 2023) conference drew to a close on Wednesday, HIV.gov continued our conversations about the latest research being presented, with updates on post-exposure prophylaxis for STIs (Doxy-PEP), implementation of HIV PrEP, and the effectiveness of U=U.
This blog is cross-posted from HIV.gov.
On Tuesday at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov continued our conversations about research highlights, including a focus on the latest about HIV vaccines. We also heard an update from the NIH Office of AIDS Research.
NIH’s Carl Dieffenbach, Ph.D., Director of the Division of AIDS at the National...
The International AIDS Society’s 12th Conference on HIV Science (IAS 2023) opened Sunday, with thousands of scientists, policy leaders, and advocates gathered to present and discuss the latest advances in HIV research. HIV.gov’s coverage of the conference began with two video conversations looking ahead to the exciting research that will be presented.
IAS Conference Highlights—Heart Disease Prevention for People with HIV, Long-acting HIV Prevention and Treatment
During the first full day of sessions at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov shared conversations on important study findings about reducing cardiovascular disease among people with HIV and the latest developments with long-acting prevention and treatment options that could one day become safe and effective alternatives to daily oral pills.
Register now to take part in an important conversation about National HIV Vaccine Awareness Day—an annual observation to recognize the many community members, health professionals, and scientists working together to develop a vaccine to prevent HIV. The HIV.gov-hosted Live with Leadership conversation will take place on Thursday, May 18, from 2:30–3:00pm ET.
To reduce the spread of HIV infection, the World Health Organization (WHO) recommends pre-exposure prophylaxis (PrEP) in populations with an annual HIV infection incidence greater than 3%. Given that the annual HIV incidence in Uganda is estimated at 0.40% (0.46% among females and 0.35% among males), there are people who may have a higher HIV risk and may benefit from PrEP but are not targeted for...
The National Institutes of Health has awarded approximately $34 million annually over the next five years to fund six independent Centers for HIV Structural Biology
HIV Research Update from CROI 2022 with NIH’s Dr. Carl Dieffenbach—Cancer Prevention, Aging, and the Future of HIV Prevention & Treatment
As the 2022 virtual Conference on Retroviruses and Opportunistic Infections came to a close, NIAID's Dr. Carl Dieffenbach joined HIV.gov for a video conversation on February 24 to discuss important findings on cancer prevention in people with HIV, research on HIV and aging, and the future of HIV prevention and treatment. Dr. Dieffenbach is the Director of the NIAID Division of AIDS.
NIH’s Dr. Carl Dieffenbach Discusses Highlights of HIV Cure, Treatment and Prevention Research from CROI 2022
In an HIV.gov video conversation on February 16, NIAID's Dr. Carl Dieffenbach discussed some of the pivotal HIV research advances presented this week at the 2022 virtual Conference on Retroviruses and Opportunistic Infections (CROI 2022). Dr. Dieffenbach, who directs the Division of AIDS, covered developments in HIV cure, treatment and prevention research. Watch the conversation and read summaries of the study findings he discussed.
Antiretroviral therapy of pregnant women and antiretroviral treatment of infants have greatly reduced the rate of mother-to-child HIV transmission, also referred to as vertical transmission. Nevertheless, although these improved rates have occurred in some countries, vertical transmission rates remain relatively high in others. This may be due to multiple factors, including access to testing, care...
The 2001 International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) Study on Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
Tuberculosis (TB) has a significant impact on maternal and infant health and is one of the leading causes of maternal death worldwide. Pregnant and postpartum women with latent TB are at a higher risk of developing active TB and pregnancy complications due to TB infection can result in babies with low birth weight, premature birth, and stillbirth. Additionally, maternal TB more than doubles the...
For pregnant women living with HIV, antiretroviral treatment (ART) is recommended to treat the infection in the mother and prevent mother-to-child HIV transmission. However, pregnancy may affect the way antiretroviral drugs are metabolized and may result in rendering the drug less effective. Studies that address the pharmacokinetics (rates of distribution, absorption, metabolism, and excretion) of...
While implementation of highly effective HIV treatment and prevention tools has reduced the HIV pandemic worldwide, development of a safe and even modestly effective vaccine would hasten progress toward a durable end of the HIV pandemic. Today, on HIV Vaccine Awareness Day, NIAID acknowledges both the progress that has been made in HIV vaccine development and the challenges that remain. We also reflect on how advances in HIV vaccinology paved the way for COVID-19 vaccine development.
Viral suppression of HIV during pregnancy is important for both maternal health and prevention of mother-to-child transmission. Antiretroviral therapy (ART) is an effective method to manage HIV, but rigorous studies on the safety and efficacy of different ART regimens in pregnant women have been limited. To address this, a recent phase 3 trial was conducted to compare three ART regimens...
On World TB Day, the National Institute of Allergy and Infectious Diseases (NIAID) joins the World Health Organization and others in acknowledging the need for continued, concerted efforts to combat tuberculosis.
HIV Prevention Study Conducted in Different Geographic Regions Among At-risk Women, Men, and Transgender People
Although the spread of HIV has slowed down thanks to risk-reduction measures, prevention efforts, and oral antiretroviral preexposure prophylaxis (PrEP), there are more than 1.5 million new cases of the human immunodeficiency virus (HIV) each year worldwide. The Antibody Mediated Prevention trials included two clinical trial cohorts, to test the ability of the monoclonal antibody VRC01 to prevent...
NIH’s Dr. Carl Dieffenbach joined HIV.gov for a conversation about the latest HIV prevention and treatment research presented there.
NIH’s Dr. Carl Dieffenbach shared highlights from HIV research presented at the 2021 virtual Conference on Retroviruses and Opportunistic Infections.
Lower Incidence of HIV Infection among Women in Epidemic Settings with Initiation and Flexible Access to PrEP
Despite major advances in testing and treating HIV, including highly effective oral pre-exposure prophylaxis, there were 1.7 million new cases of HIV in 2019. Fifty-nine percent of these occurred in sub-Saharan Africa, where a high proportion of newly infected individuals are women. In order to see if facilitating PrEP delivery decreased HIV transmission in these areas, a flexible care delivery...
New NIAID-funded research answers longstanding questions about key steps in HIV life cycle.
NIH has awarded approximately $10 million to support implementation science research which aims to reduce new HIV diagnoses in the United States.
Initial data from a large NIH-supported clinical trial offer a detailed look at the health status of people aging with HIV around the world.
NIAID and IAVI, a nonprofit scientific research organization, are collaborating to develop antibody-based products for HIV prevention and treatment.
In his final interview with HIV.gov at AIDS 2020: Virtual, NIAID's Dr. Carl Dieffenbach discussed HIV vaccine development, a new partnership to expedite development of HIV antibody combination products, NIH’s engagement in the Ending the HIV Epidemic initiative, and a look to what’s on the horizon in HIV research in the year ahead.